Literature DB >> 10794716

Mutational analysis of Lys65 of HIV-1 reverse transcriptase.

N Sluis-Cremer1, D Arion, N Kaushik, H Lim, M A Parniak.   

Abstract

Amino acid Lys(65) is part of the highly flexible beta3-beta4 loop in the fingers domain of the 66 kDa subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Recent crystal data show that the epsilon-amino group of Lys(65) interacts with the gamma-phosphate of the bound deoxynucleoside triphosphate ('dNTP') substrate [Huang, Chopra, Verdine and Harrison (1998) Science 282, 1669-1675]. In order to biochemically define the function of RT Lys(65), we have used site-specific mutagenesis to generate RT with a variety of substitutions at this position, including K65E, K65Q, K65A and K65R. Kinetic analyses demonstrate that if Lys(65) in RT is substituted with an amino acid other than arginine the enzyme exhibits dramatic decreases in the binding affinity (K(m)) for all dNTP substrates, in RT catalytic efficiency (k(cat)/K(m)) and in the mutant enzyme's ability to carry out pyrophosphorolysis, the reverse reaction of DNA synthesis. The pH optimum for the DNA polymerase activity of K65E RT was 6.5, compared to 7.5 for the wild-type enzyme, and 8.0 for the K65R, K65A and K65Q mutants. Molecular modelling studies show that mutations of Lys(65) do not affect the geometry of the loop's alpha-carbon backbone, but rather lead to changes in positioning of the side chains of residues Lys(70) and Arg(72). In particular, Glu in K65E can form a salt bridge with Arg(72), leading to the diminution of the latter residue's interaction with the alpha-phosphate of the dNTP residue. This alteration in dNTP-binding may explain the large pH-dependent changes in both dNTP-binding and catalytic efficiency noted with the enzyme. Furthermore, the K65A, K65Q and K65E mutant enzymes are 100-fold less sensitive to all dideoxynucleoside triphosphate ('ddNTP') inhibitors, whereas the K65R mutation results in a selective 10-fold decrease in binding of ddCTP and ddATP only. This implies that mutations at position 65 in HIV-1 RT influence the nucleotide-binding specificity of the enzyme.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794716      PMCID: PMC1221038     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  22 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Human immunodeficiency virus reverse transcriptase: steady-state and pre-steady-state kinetics of nucleotide incorporation.

Authors:  J E Reardon
Journal:  Biochemistry       Date:  1992-05-12       Impact factor: 3.162

Review 3.  Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo.

Authors:  R S Goody; B Müller; T Restle
Journal:  FEBS Lett       Date:  1991-10-07       Impact factor: 4.124

Review 4.  HIV resistance to reverse transcriptase inhibitors.

Authors:  E De Clercq
Journal:  Biochem Pharmacol       Date:  1994-01-20       Impact factor: 5.858

5.  Crystal structures of open and closed forms of binary and ternary complexes of the large fragment of Thermus aquaticus DNA polymerase I: structural basis for nucleotide incorporation.

Authors:  Y Li; S Korolev; G Waksman
Journal:  EMBO J       Date:  1998-12-15       Impact factor: 11.598

6.  The rapid generation of oligonucleotide-directed mutations at high frequency using phosphorothioate-modified DNA.

Authors:  J W Taylor; J Ott; F Eckstein
Journal:  Nucleic Acids Res       Date:  1985-12-20       Impact factor: 16.971

7.  Side chains involved in catalysis of the polymerase reaction of DNA polymerase I from Escherichia coli.

Authors:  A H Polesky; M E Dahlberg; S J Benkovic; N D Grindley; C M Joyce
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

8.  Human immunodeficiency virus reverse transcriptase. A kinetic analysis of RNA-dependent and DNA-dependent DNA polymerization.

Authors:  J E Reardon
Journal:  J Biol Chem       Date:  1993-04-25       Impact factor: 5.157

9.  Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

Authors:  Z Gu; Q Gao; H Fang; H Salomon; M A Parniak; E Goldberg; J Cameron; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction.

Authors:  E J Arts; X Li; Z Gu; L Kleiman; M A Parniak; M A Wainberg
Journal:  J Biol Chem       Date:  1994-05-20       Impact factor: 5.157

View more
  31 in total

1.  K65R and K65A substitutions in HIV-1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP misinsertion and mispaired primer extension efficiencies.

Authors:  Scott J Garforth; Robert A Domaoal; Chisanga Lwatula; Mark J Landau; Amanda J Meyer; Karen S Anderson; Vinayaka R Prasad
Journal:  J Mol Biol       Date:  2010-06-09       Impact factor: 5.469

2.  Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.

Authors:  J L Hammond; D L Koontz; H Z Bazmi; J R Beadle; S E Hostetler; G D Kini; K A Aldern; D D Richman; K Y Hostetler; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Chain-terminating dinucleoside tetraphosphates are substrates for DNA polymerization by human immunodeficiency virus type 1 reverse transcriptase with increased activity against thymidine analogue-resistant mutants.

Authors:  Peter R Meyer; Anthony J Smith; Suzanne E Matsuura; Walter A Scott
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to the antiviral drug foscarnet.

Authors:  Egor P Tchesnokov; Christian Gilbert; Guy Boivin; Matthias Götte
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection.

Authors:  Scott J Garforth; Tae Woo Kim; Michael A Parniak; Eric T Kool; Vinayaka R Prasad
Journal:  J Mol Biol       Date:  2006-09-27       Impact factor: 5.469

6.  In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

Authors:  Urvi M Parikh; Dianna L Koontz; Chung K Chu; Raymond F Schinazi; John W Mellors
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations.

Authors:  Urvi M Parikh; Lee Bacheler; Dianna Koontz; John W Mellors
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

8.  Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine.

Authors:  Jeffrey D Meteer; Raymond F Schinazi; John W Mellors; Nicolas Sluis-Cremer
Journal:  Antiviral Res       Date:  2013-11-07       Impact factor: 5.970

9.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

10.  Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance.

Authors:  Kalyan Das; Rajiv P Bandwar; Kirsten L White; Joy Y Feng; Stefan G Sarafianos; Steven Tuske; Xiongying Tu; Arthur D Clark; Paul L Boyer; Xiaorong Hou; Barbara L Gaffney; Roger A Jones; Michael D Miller; Stephen H Hughes; Eddy Arnold
Journal:  J Biol Chem       Date:  2009-10-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.